Educational Fund

MAPS coordinates a number of educational projects, including publishing the tri-annual MAPS Bulletin, sharing a monthly Email Newsletter, publishing books relevant to our mission, sponsoring psychedelic …

Ibogaine Fund

MAPS is studying the effects of ibogaine-assisted therapy as a treatment for severe opiate addiction. At present, there is relatively little data that rigorously evaluates the long-term outcome of ibogaine-assisted …

Medical Marijuana Fund

MAPS is seeking to develop whole-plant marijuana into an FDA-approved prescription medicine. The FDA has approved a MAPS-sponsored protocol for evaluating the safety and effectiveness of five strains of …

LSD Psychotherapy Research Fund

MAPS is currently sponsoring the first clinical study of LSD in humans in over 35 years. Based in Switzerland and led by Principal Investigator Peter Gasser, M.D., this study is exploring the safety and …

MDMA-Assisted Therapy Research Fund

Developing MDMA (3,4-methylenedioxymethamphetamine) into an FDA-approved prescription medicine for PTSD is our top funding priority. We are currently conducting or developing clinical trials of MDMA-assisted …